The legal history of cannabis in the United States is not a story about a plant. It is a story about race, politics, bureaucratic self-preservation, and the slow, grinding machinery of democratic reform. The substance that was legal, widely used, and listed in the U.S. Pharmacopeia for decades became, through a series of deliberate political choices, one of the most heavily penalized drugs in the federal schedule — classified alongside heroin, above cocaine, methamphetamine, and fentanyl.
Understanding how cannabis arrived at its current legal status — legal in most states, illegal under federal law, rescheduled but not descheduled, taxed but not fully banked — requires understanding the specific decisions, the specific people, and the specific political calculations that built the prohibition apparatus over the course of a century.
Before Prohibition: Cannabis in Early America
Cannabis has been cultivated in North America since the colonial era. Hemp — the low-THC variety of the cannabis plant — was a major agricultural commodity. Virginia, Massachusetts, and Connecticut all passed laws in the 1600s requiring farmers to grow hemp, which was used for rope, sails, textiles, and paper. George Washington grew hemp at Mount Vernon. Thomas Jefferson grew it at Monticello. The Declaration of Independence was reportedly drafted on hemp paper.
Cannabis preparations also had a long history in American medicine. Cannabis tinctures and extracts were widely available in pharmacies throughout the 19th century, prescribed for pain, nausea, insomnia, and a variety of other ailments. By 1850, cannabis was listed in the United States Pharmacopeia, the official compendium of approved medications.
The shift from commonplace commodity to prohibited substance did not happen because of a scientific breakthrough revealing hidden dangers. It happened because of political and racial dynamics in the early 20th century.
The Seeds of Prohibition (1910-1937)
Mexican Immigration and Racial Panic
The first wave of cannabis prohibition in the United States was driven not by public health concerns but by anti-Mexican sentiment. Following the Mexican Revolution of 1910, a surge of Mexican immigration into the American Southwest brought with it the practice of smoking cannabis for recreational and medicinal purposes — a practice that was largely unfamiliar to Anglo-Americans, who were more accustomed to cannabis in tincture form.
Local and state officials in border states began associating cannabis smoking with Mexican immigrants and, by extension, with crime, violence, and moral decay. El Paso, Texas, passed one of the first local cannabis bans in 1914. Other border states followed. The language used was explicitly racial — newspapers and politicians referred to the drug as “marihuana” (a Spanish-language term) specifically to emphasize its foreign origins and distance it from the familiar “cannabis” that Americans had been using medicinally for decades.
By 1931, 29 states had enacted some form of cannabis prohibition, primarily driven by these racial and nativist anxieties rather than by medical evidence.
Harry Anslinger and the Federal Bureau of Narcotics
The man most responsible for transforming localized cannabis restrictions into a national prohibition regime was Harry J. Anslinger, the first commissioner of the Federal Bureau of Narcotics (FBN), appointed in 1930.
Anslinger faced a bureaucratic problem: the FBN was created during Prohibition, and its original mandate focused on opiates and cocaine. With alcohol prohibition ending in 1933 and the opiate problem relatively contained, Anslinger needed a new justification for his agency’s budget and personnel. Cannabis provided that justification.
Anslinger launched a public campaign against cannabis that was remarkable for its intensity, its racism, and its complete disconnection from scientific evidence. He provided lurid stories to newspapers about cannabis-induced violence and insanity, many of them fabricated or grossly distorted. His public testimony included statements explicitly linking cannabis to racial minorities and jazz musicians — statements that are well-documented in FBN archives and Congressional records.
In 1936, the propaganda film Reefer Madness was produced (originally as Tell Your Children), depicting cannabis use as a direct pathway to insanity, violence, and death. While the film was not directly produced by the FBN, it reflected and amplified the narrative that Anslinger had cultivated.
The Marihuana Tax Act of 1937
Anslinger’s campaign culminated in the Marihuana Tax Act of 1937, the first federal legislation effectively criminalizing cannabis. The act did not technically ban cannabis — it imposed a tax on cannabis transactions that was structured to make legal compliance virtually impossible. Anyone possessing cannabis without having paid the tax faced severe penalties.
The legislative process was notable for what it excluded. The American Medical Association opposed the bill, with its legislative counsel Dr. William C. Woodward testifying that the AMA had not been consulted during drafting and that the bill would impede medical research. Woodward’s testimony was largely ignored. The bill passed the House after less than two minutes of floor debate, with one representative reportedly asking, “What is this bill about?” and receiving the answer, “It has something to do with a thing called marihuana. I believe it is a narcotic of some kind.”
The Marihuana Tax Act effectively ended legal cannabis commerce and medical use in the United States. Cannabis was removed from the U.S. Pharmacopeia in 1942.
The War on Drugs (1970-1990s)
The Controlled Substances Act of 1970
The modern architecture of drug prohibition was established by the Controlled Substances Act (CSA), signed into law by President Richard Nixon in 1970. The CSA created the scheduling system that remains in effect today, classifying drugs into five schedules based on their potential for abuse, accepted medical use, and safety profile.
Cannabis was placed in Schedule I — the most restrictive category, reserved for substances deemed to have high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. Schedule I also includes heroin, LSD, and ecstasy. Notably, cocaine (Schedule II), methamphetamine (Schedule II), and fentanyl (Schedule II) were all placed in less restrictive categories than cannabis.
The scheduling decision was supposed to be temporary. Nixon appointed a commission — the National Commission on Marihuana and Drug Abuse, chaired by former Pennsylvania Governor Raymond Shafer — to study the issue and recommend a permanent classification. The Shafer Commission conducted an extensive review and, in its 1972 report, unanimously recommended decriminalizing personal possession and use of cannabis, concluding that the drug was not the danger that prohibition advocates claimed.
Nixon rejected the commission’s recommendations. According to recordings from the Nixon White House (released through the National Archives), Nixon’s opposition to cannabis was tied to his broader political strategy. He reportedly told his chief of staff H.R. Haldeman that the drug issue could be used to target specific populations. A 1994 interview with Nixon’s domestic policy advisor John Ehrlichman, published by journalist Dan Baum in Harper’s Magazine in 2016, further illustrated the political calculus behind the War on Drugs.
Mandatory Minimums and Mass Incarceration
The 1980s and 1990s saw a dramatic escalation of cannabis penalties under the broader War on Drugs framework. The Anti-Drug Abuse Act of 1986, signed by President Reagan, established mandatory minimum sentences for drug offenses, including cannabis. Possession of 100 cannabis plants triggered a mandatory minimum of five years in federal prison. Subsequent legislation in 1988 added the “three strikes” provision for repeat drug offenders.
These policies produced a massive expansion of the incarcerated population. According to data from the Bureau of Justice Statistics, the number of people incarcerated for drug offenses in the United States increased from approximately 40,000 in 1980 to over 450,000 by 2000. Cannabis offenses accounted for a significant portion of these incarcerations — the FBI’s Uniform Crime Reports show that cannabis arrests accounted for nearly half of all drug arrests throughout this period.
The racial disparities were stark. Despite roughly equal rates of cannabis use across racial groups (documented by the National Survey on Drug Use and Health), Black Americans were arrested for cannabis possession at 3.73 times the rate of white Americans, according to a comprehensive 2013 ACLU analysis. In some jurisdictions, the disparity exceeded 8:1.
The Compassionate IND Program: A Crack in the Wall
While the War on Drugs was escalating penalties, a small federal program was quietly providing cannabis to a handful of American patients — creating a remarkable legal contradiction.
The Compassionate Investigational New Drug (IND) program was established in 1978 following a lawsuit by Robert Randall, a glaucoma patient who successfully argued that his cannabis use was a medical necessity. Under the program, the federal government supplied cannabis — grown at the University of Mississippi — to approved patients for medical use.
At its peak, the program served approximately 15 patients. In 1992, the George H.W. Bush administration closed the program to new applicants after a surge of applications from AIDS patients. The patients already enrolled were allowed to continue receiving federal cannabis, and as of the mid-2020s, a small number of surviving participants still receive monthly shipments of cannabis from the federal government.
The Compassionate IND program was never large enough to constitute a meaningful medical cannabis program, but its existence was legally and symbolically significant. The federal government was simultaneously classifying cannabis as having “no currently accepted medical use” (Schedule I) while providing it as medicine to specific patients. This contradiction became a recurring argument in the legalization movement.
The State-Level Revolution (1996-Present)
Medical Cannabis: California Leads
On November 5, 1996, California voters passed Proposition 215, the Compassionate Use Act, making California the first state to legalize medical cannabis. The proposition passed with 55.6% of the vote, allowing patients with a physician’s recommendation to possess and cultivate cannabis for conditions including cancer, AIDS, glaucoma, and chronic pain.
Proposition 215 was revolutionary not because of its specific provisions — which were broad and loosely defined — but because it demonstrated that direct democracy could override federal drug policy. The federal government’s response was hostile. The Clinton administration threatened to revoke the prescribing licenses of physicians who recommended cannabis, but a federal court injunction blocked this threat on First Amendment grounds.
The California model spread. By 2000, seven additional states had passed medical cannabis laws. The pace accelerated through the 2000s and 2010s.
Medical Cannabis Expansion Timeline
| Year | State | Method |
|---|---|---|
| 1996 | California | Ballot initiative |
| 1998 | Alaska, Oregon, Washington | Ballot initiatives |
| 1999 | Maine | Ballot initiative |
| 2000 | Hawaii, Colorado, Nevada | Legislature / ballot |
| 2004 | Montana, Vermont | Ballot / legislature |
| 2006 | Rhode Island | Legislature |
| 2007 | New Mexico | Legislature |
| 2008 | Michigan | Ballot initiative |
| 2010 | New Jersey, Arizona, DC | Legislature / ballot |
| 2012 | Connecticut, Massachusetts | Legislature / ballot |
| 2013 | Illinois, New Hampshire | Legislature |
| 2014 | New York, Minnesota, Maryland | Legislature |
| 2016 | Multiple states | Various |
| 2018-2025 | Continued expansion | Various |
By 2025, 38 states plus the District of Columbia had enacted medical cannabis programs, covering the vast majority of the American population.
Recreational Legalization: Colorado and Washington Lead
On November 6, 2012, Colorado and Washington became the first states to legalize cannabis for adult recreational use, passing Amendment 64 and Initiative 502 respectively. This represented a fundamental shift from medical accommodation to full legalization — removing the requirement for a medical condition or physician recommendation.
Colorado’s first recreational dispensaries opened on January 1, 2014. The state’s experience in the first year became a closely watched case study. Cannabis tax revenue exceeded projections. Violent crime did not increase. Traffic fatalities did not spike. Youth use rates remained stable. The apocalyptic predictions that prohibition advocates had relied on for decades failed to materialize.
This data provided powerful evidence for legalization advocates in other states. Oregon, Alaska, and the District of Columbia legalized recreational cannabis in 2014. California, Massachusetts, Maine, and Nevada followed in 2016. By 2025, 24 states and the District of Columbia had legalized adult-use cannabis, with several additional states likely to follow.
The Economic Impact
The economic argument for legalization has proven powerful. According to data compiled by cannabis analytics firms, total legal cannabis sales in the United States reached approximately $30 billion annually by 2024. State tax revenues from cannabis have been substantial — Colorado alone has collected over $2 billion in total cannabis tax revenue since 2014, with funds directed toward education, public health, and infrastructure.
The industry directly employs an estimated 400,000-500,000 workers across cultivation, manufacturing, retail, and ancillary services. In many states, cannabis has become a significant contributor to the local economy, particularly in rural communities where cultivation operations have replaced declining agricultural or industrial enterprises.
Federal Status: The Unresolved Contradiction
Despite the state-level revolution, cannabis remains a controlled substance under federal law. This creates a web of legal contradictions that affect every aspect of the industry.
Banking and Financial Services
Because cannabis is federally illegal, banks and credit unions (which are federally regulated) risk money laundering charges if they knowingly service cannabis businesses. The result: a multi-billion-dollar industry operating largely in cash, creating security risks, accounting challenges, and barriers to normal business operations.
The SAFE Banking Act, which would protect financial institutions from federal penalties for servicing state-legal cannabis businesses, has passed the House of Representatives multiple times but has repeatedly stalled in the Senate. As of early 2026, cannabis businesses continue to operate under significant banking constraints.
Section 280E
Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting normal business expenses on their federal tax returns. For cannabis companies, this means effective federal tax rates that can exceed 70% — a crippling burden that has contributed to widespread financial distress across the industry.
The Rescheduling Process
In October 2022, President Biden directed the Department of Health and Human Services (HHS) to review the scheduling of cannabis. HHS completed its review and recommended rescheduling cannabis to Schedule III, which would acknowledge its accepted medical use and lower the regulatory burden.
The Drug Enforcement Administration published a proposed rule in May 2024 to move cannabis from Schedule I to Schedule III. If finalized, rescheduling would eliminate the 280E tax burden for cannabis businesses, facilitate clinical research by reducing regulatory barriers, and provide symbolic recognition that the federal government accepts cannabis’s medical utility.
However, rescheduling to Schedule III would not legalize cannabis at the federal level. Cannabis would remain a controlled substance requiring prescriptions, and the state-level recreational markets would still technically conflict with federal law. Full federal legalization or descheduling would require Congressional action.
The Cole Memorandum and Federal Enforcement
Federal enforcement of cannabis laws in states with legal programs has been governed more by executive discretion than by legislative clarity. The Cole Memorandum (2013), issued by Deputy Attorney General James Cole during the Obama administration, directed federal prosecutors to deprioritize cannabis enforcement in states with robust regulatory frameworks, focusing federal resources on priorities like preventing diversion to minors and interstate trafficking.
The Trump administration’s first Attorney General, Jeff Sessions, rescinded the Cole Memorandum in January 2018, creating uncertainty across the industry. However, no significant federal enforcement actions against state-legal cannabis businesses followed the rescission, and subsequent attorneys general have largely maintained a hands-off approach.
Social Equity: The Unfinished Business
As legalization has expanded, the profound injustice of the War on Drugs has become impossible to ignore. The communities most devastated by cannabis enforcement — predominantly Black and Latino neighborhoods — have often been excluded from the economic benefits of legalization, while the entrepreneurs building wealth in the legal industry are disproportionately white and affluent.
Multiple states have attempted to address this through social equity provisions in their legalization frameworks. Illinois, New York, New Jersey, and California have all implemented programs designed to prioritize cannabis licenses for applicants from communities disproportionately affected by prohibition, provide expungement of prior cannabis convictions, and direct a portion of cannabis tax revenue to impacted communities.
The results have been mixed. Many social equity programs have been plagued by bureaucratic delays, insufficient funding, and regulatory barriers that make it difficult for under-resourced applicants to compete with well-capitalized operators. New York’s adult-use market, which placed social equity at the center of its legalization framework, experienced significant delays in license processing and market launch, leading to a thriving illicit market that undercut the very equity applicants the program was designed to support.
According to data from Leafly’s annual cannabis jobs report, minorities hold approximately 30% of executive positions in the cannabis industry — an improvement over earlier years but still below proportional representation, particularly given that minority communities bore the brunt of prohibition enforcement.
Expungement has been more successful as a policy tool. California, Illinois, and several other states have expunged or are in the process of expunging hundreds of thousands of cannabis convictions, with some jurisdictions using automated processes to clear records without requiring individual petitions.
Where Things Stand
As of early 2026, the legal landscape of cannabis in America is defined by contradictions:
- Cannabis is legal in the majority of states but illegal under federal law.
- The federal government has proposed acknowledging its medical utility by rescheduling to Schedule III while millions of Americans buy it recreationally at state-licensed stores.
- The industry generates tens of billions in annual revenue but cannot fully access the banking system.
- Social equity is a stated priority of most legalization frameworks but remains poorly implemented in practice.
- Cannabis arrests still occur — the FBI reports hundreds of thousands of cannabis-related arrests annually, overwhelmingly for possession, overwhelmingly in states without legal frameworks, and overwhelmingly affecting communities of color.
The trajectory is unmistakable. Public support for legalization, which stood at 25% in 1995 according to Gallup polling, has risen to over 70% in recent surveys. State-level legalization continues to expand. Federal reform, while slow, is moving in the direction of reduced restriction. And the next generation of voters — who have grown up in a world where legal cannabis is normal — show even higher support.
The question is no longer whether American cannabis prohibition will end. It is how long the contradictions will persist before federal policy catches up with state-level reality, public opinion, and the basic logic of regulatory coherence. The history of cannabis legalization is, in many ways, still being written — but the ending is no longer in doubt.